Add Tribune As Your Trusted Source
TrendingVideosIndia
Opinions | CommentEditorialsThe MiddleLetters to the EditorReflections
UPSC | Exam ScheduleExam Mentor
State | Himachal PradeshPunjabJammu & KashmirHaryanaChhattisgarhMadhya PradeshRajasthanUttarakhandUttar Pradesh
City | ChandigarhAmritsarJalandharLudhianaDelhiPatialaBathindaShaharnama
World | ChinaUnited StatesPakistan
Diaspora
Features | The Tribune ScienceTime CapsuleSpectrumIn-DepthTravelFood
Business | My Money
News Columns | Straight DriveCanada CallingLondon LetterKashmir AngleJammu JournalInside the CapitalHimachal CallingHill ViewBenchmark
Don't Miss
Advertisement

Restricted use of Covovax for 12-17 age group

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Yearly Premium ₹999 ₹349/Year
Yearly Premium $49 $24.99/Year
Advertisement

New Delhi, March 4

Advertisement

An expert panel of the Drugs Controller General of India (DCGI) on Friday recommended grant of emergency use authorisation to Serum Institute of India’s Covid-19 shot Covovax for 12-17 year olds.

Advertisement

The DCGI had earlier approved Covovax for restricted emergency use in adults on December 28. The vaccine has not been included in the national drive yet. The subject expert committee on Covid of the Central Drugs Standard Control Organisation met today to take up SII’s application and recommended EUA to Covovax in young adolescents. —

Advertisement
Show comments
Advertisement